A Phase 1 Dose Escalation Trial of ZG006 in Patients With Small Cell Lung Cancer
Phase 1
30
about 2.2 years
18–75
6 sites in CA, FL, KY +2
What this study is about
This trial is testing a treatment called ZG006 for people with small cell lung cancer who have not responded to or cannot tolerate standard treatments. The goal is to find the best dose of ZG006 that can be safely used in future studies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ZG006
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Maximum Tolerated Dose (MTD) of ZG006, Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs), The incidence of dose-limiting toxicity (DLT)
Secondary: AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of ZG006, Disease control rate (DCR), Duration of response (DOR), Maximum plasma concentration (Cmax) of ZG006, Objective response rate (ORR), Terminal phase half-life (t1/2) of ZG006, Time to peak concentration (Tmax)
Oncology